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Abstract
Background: Previous studies indicate that alterations in Human Leukocyte Antigen (HLA) class
I expression are frequent in colorectal tumors. This would suggest serious limitations for
immunotherapy-based strategies involving T-cell recognition. Distinct patterns of HLA surface
expression might conceal different immune escape mechanisms employed by the tumors and are
worth further study.
Method: We applied four-color multiparameter flow cytometry (FCM), using a large panel of
alloantigen-specific anti-HLA-A and -B monoclonal antibodies, to study membranous expression of
individual HLA alleles in freshly isolated colorectal cancer cell suspensions from 21 patients.
Results: Alterations in HLA class I phenotype were observed in 8 (38%) of the 21 tumors and
comprised loss of a single A or B alleles in 4 cases, and loss of all four A and B alleles in the other
4 cases. Seven of these 8 tumors were located on the right side of the colon, and those showing
loss of both HLA-A and -B membranous expression were all of the MSI-H phenotype.
Conclusion: FCM allows the discrimination of complex phenotypes related to the expression of
HLA class I. The different patterns of HLA class I expression might underlie different tumor
behavior and influence the success rate of immunotherapy.
Background
The high morbidity and mortality of colorectal cancer
underscores the need for new, more effective adjuvant
treatment strategies. One promising approach centers on
boosting cell-mediated anti-tumor immune responses.
Numerous tumor-associated peptides have been identi-
fied that can be specifically targeted with vaccine-based
immune therapy strategies [1]. Specifically, such strategies
may be employed for colorectal tumors with a so-called
microsatellite instability-high (MSI-H) phenotype [2,3].
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match repair mechanism which results in an abundance
of frame shift mutations of (coding) microsatellite repeat
sequences. The peptides produced by such frame shift
mutations can evoke specific anti-tumor immune
responses [4-6]. Nevertheless, however promising the
approach, its success is dependent on the extent of opera-
tional immune surveillance mechanisms in the tumor.
Human Leukocyte Antigen (HLA) class I molecules are of
major importance for cell-mediated anti-tumor immune
responses. Expression of HLA class I/β2-microglobulin
(β2-m) complexes carrying tumor-specific peptides is a
prerequisite for adaptively matured cytotoxic T cells
(CTLs) to be able to recognize tumor cells [7]. HLA class I
antigens are encoded by a family of highly polymorphic
genes, with each allele responsible for a different reper-
toire of antigen presentation. Thus, even the loss of a sin-
gle allele could potentially allow the escape from an
antigen-specific anti-tumor response. Loss of expression
of HLA class I molecules has been frequently reported for
colorectal tumors [8-10]. This would therefore represent a
serious limitation for vaccine-based anti-tumor therapies.
However, these studies have primarily been based on
immunohistochemical analyses (IHC) and therefore have
a number of intrinsic limitations [11]. HLA staining by
IHC is often strongly cytoplasmic, which could poten-
tially obscure functionally relevant membranous co-
expression and result in a false negative interpretation.
Additionally, adequate study by IHC is hampered by the
limited choice of antibodies (Abs) available for the analy-
sis of formalin-fixed, paraffin-embedded tissue and
importantly, despite the fact that the use of fresh frozen
tissue allows the employment of a higher number of Abs,
complete panels of the latter are not yet readily available.
Another important consideration is that certain HLA class
I complexes also mediate inhibitory signals through
receptors expressed by CTLs and natural killer (NK) cells,
averting the so-called 'missing self' recognition [12,13].
Hence, an effective tumor immune escape mechanism
could occur through a subtle alteration of the tumor cell
HLA phenotype, circumventing both CTL and NK cell
attack. Thus far, it has not been technically feasible to
study these intricacies comprehensively, and the molecu-
lar mechanisms proposed to generate HLA alterations
have been contradictory, as they could not always account
for the observed phenotypic alterations.
In an attempt to overcome these limitations, we have
employed four-color multiparameter flow cytometry
(FCM) on freshly isolated tumor cells using a large panel
of human alloantigen specific monoclonal antibodies
(mAbs). This approach has numerous advantages: i) it
allows for the study of complex phenotypes, ii) FCM is
much more sensitive than IHC, and iii) it is possible to
study membranous HLA expression alone. Using the FCM
technique we were able to distinguish two distinct pat-




Fresh tumor samples, macroscopically identified by a
pathologist (HM), were collected from 21 patients with
surgical resections between 2001 and 2003 at the depart-
ment of Surgery of the Leiden University Medical Center.
Peripheral blood samples were collected from 15 patients
pre-operatively. There was no pre-selection of the patients
included in this series. All patients agreed to participate
and provided written informed consent, and the study
was approved by the local ethical review committee.
HLA genotyping
DNA was extracted from peripheral blood leucocytes
using a standard salting-out procedure. Patients were
HLA-A and -B genotyped using PCR-sequence-specific oli-
gonucleotide probes (Dynal Biotech Ltd., Wirral, U.K.), as
described previously [14]. Patient HLA genotype is shown
on Table 2.
Tissue dissociation
Minced fresh tumor samples were weighed, cut in frag-
ments of approximately 1 mm3, and incubated over night
at 4°C with 5 ml/g serum-free RPMI 1640 medium (Inv-
itrogen, Paisley, UK) supplemented with 50 IU/ml peni-
cillin-streptomycin (ICN Biomedicals Inc., Aurora), 128
U/ml collagenase type I (Sigma-Aldrich, St. Louis, MO),
100 U/ml hyaluronidase type V Sigma-Aldrich), and 250
U/ml DNAse I (Sigma-Aldrich). The next day, the same
suspension was incubated for 90 min at 37°C followed by
two washing steps with RPMI including 10% FCS (Invit-
rogen) to block proteolysis, and Hank's Balanced Salt
Solution (Sigma-Aldrich). Cells were incubated for
another 15 min at 37°C with 0.25% Trypsin (Invitrogen),
1 mM EDTA in Hank's Balanced Salt Solution, chilled to
4°C, and washed with RPMI with 10% FCS. Finally, the
suspension was filtered through a 100 μm sieve (Ver-
seidag-Industrietextilien GmbH, Kempen, Germany) and
used immediately for flow cytometry.
Anti-HLA antibodies
A large panel of human and mouse anti-HLA mAbs was
used for FCM (Table 1), some of which were previously
described [15-17]. To establish the activity of the human
mAbs (hu-mAb), peripheral blood lymphocytes were iso-
lated from multiparous women who had developed HLA
alloantigen specific antibodies during pregnancy, and the
lymphocytes transformed with Epstein Barr virus (EBV).
HLA antibody producing EBV cell lines were stabilized byPage 2 of 12
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hu-mAbs was determined by testing these antibodies with
a large (n > 240) panel of HLA-typed peripheral blood
mononuclear cell suspensions in a conventional comple-
ment dependent microcytotoxicity (CDC) assay [19]. On
the basis of the mAb reactivity patterns, suitable HLA
alloantigen-specific sub-panels were chosen for each
colorectal cancer patient's HLA phenotype, as well as
proper negative isotype controls. Several mAbs were used
to address the same HLA allelic products to rule out arti-
facts caused by differences in mAb in specificity/affinity.
Flow cytometry
A seven-step, four-color staining procedure was per-
formed as described previously [20]. Simultaneous labe-
ling of HLA, β2m, DNA, and the intermediate filaments
Table 1: Monoclonal anti-human antibodies used for flow cytometry analysis of HLA Class I expression
mAb species isotype HLA specificity reference
116.5.28 M IgG2a Bw4 *
126/39 M IgG3 Bw6 *
A11.1M M IgG3 A11, A24 18
BB7.2 M IgG2b A2, Aw68 18
Bbm1 M IgG2b β 2-m 18
GAP.A3 M IgG2a A3 18
MA2.1 M IgG1 A2, B17 18
SFR8.B6 R IgG2b Bw6 18
W6/32 M IgG2a HLA -A,-B,-C 18
BV 8E9 H IgM,κ A28, A33, A34 16
BVK 5B10 H IgM,κ B8 †
BVK 5C4 H IgM,κ A80, A9 21
DMS 4G2 H IgG1,λ B62, B35 17
FVS 4G4 H IgM,κ B15, B17, B5, B37, B16, B18, B35 16
GK 31F12 H IgM,κ B13 16
GV 5D1 H IgG1,λ A1, A9 16
GVK 10H7 H IgM,λ B5, B35, B18, B37, B38, B14, B77, B72, B53 †
GVK 4H11 H IgM,κ B35, B62, B5, B16, B18, B37, B53, B70, B14 †
HDG 2G7 H IgG1,κ A19, B17, B63, B47 16
HDG 8D9 H IgG1,λ B51, B35 16
IN 2D12 H IgM,λ B15, B35, B21, B70 16
JOK 3H5 H IgM,λ B40, B21, B13, B12, B41, B70 †
KAL 3D5 H IgG1,λ B51, B52, B77 17
KG 30A7 H IgM,λ B27, B12, B14, B49 18
KLL 5E10 H IgG1,κ B51, B52 †
MUS 4H4 H IgG1,λ Bw4 †
Nie 44B8 H IgM,κ A10 16
OK 1C9 H IgM,λ A3, A11, A33, A31, A26 18
OK 2F3 H IgM,κ A3 16
OK 2H12 H IgM,κ A11, A3, A36, A32, A1 16
OK 3C8 H IgM,κ A3, A11, A32, A36, A31 16
OK 4F10 H IgM,κ A1, A3, A11, A31, A33, A26, A29, A30 †
OK 4F9 H IgM,κ A1, A36, A3, A11, A34, A66, A26, A29, A30, A31, A33 16
OK 5A3 H IgM,λ A1, A3, A11, A24, A36 18
OK 6H10 H IgM,κ B15, B21, B56, B35, B72 16
OK 6H12 H IgM,κ B21, B56, B70, B35, B62 18
ROU 9A6 H IgG3,λ B12, B13, B40, B21, B41 †
SN 607D8 H IgG1,κ A2, A28 16
SN 66E3 H IgM,κ A2, A28 16
vD1F11 H IgM,λ B62, B35, B57, B21, B56, B70, B55 16
VTM 1F11 H IgG1,κ B27, B7, B60 †
VTM 4D9 H IgG1,κ B7, B27 †
VTM 9A10 H IgG1,κ B7, B27 †
WAR 5D5 H IgG1,κ B7, B27, B42, B55 †
WIM 8E5 H IgG1,κ A1, A10, A11, A9, A29, A30, A31, A33 †
WK 3D10 H IgM,κ A2, A3, A23, A31, B7, B13, B17, B21, B40, B62 †
WK 4E3 H IgM,λ A locus (not A1, A24) †
M, Mouse; H, Human; R, Rat; *, kindly donated by Dr. K. Gelsthorpe, Sheffield, U.K.; †, this paper.Page 3 of 12
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expression in keratin positive (tumor) epithelial cells
from those in vimentin positive 'normal' cells (leucocytes
and fibroblasts). Importantly, we specifically analyzed
membranous expression since cells were only permeabi-
lized after HLA immunostaining making the cytoplasm
inaccessible to the anti-HLA Abs. In 15 cases, we used a
complete panel of human and mouse anti-HLA mAbs,
and in another 5 cases we used mouse mAbs (mu-mAb)
because the HLA genotype was not known prior to tumor
resection. Reagents used were biotinylated goat anti-
mouse and anti-human mAbs (Southern Biotechnology
Associates, Birmingham, AL), Streptavidin-allophycocy-
anin (APC) (Molecular Probes, Eugene, OR), goat F(ab')2
anti-mouse IgG1 and IgG2a-RPE, and goat F(ab')2 anti-
mouse IgG2b or IgG1-FITC polyclonal antibodies (SBA),
paraformaldehyde (Merck, Whitehouse Station, NJ), L-α-
lysophosphatidylcholine (lysolecithin, Sigma-Aldrich),
RNase (Sigma-Aldrich), and propidium iodide (Calbio-
chem) were used. We used three different combinations
of anti-keratin and anti-vimentin mAbs to prevent cross-
reactivity of the secondary reagents with the anti-HLA
antibody. The first combined anti-keratin IgG1 mAbs M9,
M20, and AE1/AE3 (Chemicon International Inc., Temec-
ula, CA) and anti-vimentin Ig2b mAb V9; the second com-
bined anti-keratin IgG2a mAbs CAM5.2 (BD Biosciences,
San Jose, CA) and anti-vimentin IgG1 mAb V9; and the
third combined anti-keratin IgG2a mAb CAM5.2 and
anti-vimentin Ig2b mAb V9. Clones M9, M20, and V9
were established at the Department of Pathology, Leiden
University Medical Center, The Netherlands, and are com-
mercially available from ARA, Alphen a/d Rijn, the Neth-
erlands. For each sample, measurements from 10,000–
20,000 single cells were collected using a standard FACS-
Calibur™ flow cytometer (BD Biosciences). Data were ana-
lyzed using WinList 5.0 and ModFit 3.0 software (Verity
Software House Inc., Topsham, ME). After electronic gat-
ing on keratin and vimentin content, single parameter his-
tograms were obtained for DNA content and HLA
expression. Geomean APC fluorescence intensity values
(MFI) were subtracted by MFI values from proper negative
controls. These ratios were used to calculate the relative
expression value (REV) of keratin positive (ker+) cells
compared to vimentin positive (vim+) cells.
Immunohistochemistry
A standard three-step, indirect immunohistochemistry
was performed on consecutive 4 μm formalin-fixed, par-
affin-embedded tissue sections mounted on aminopro-
pylethoxysilane coated glass slides. Antigen retrieval was
performed in boiling citrate 10 mM (pH 6.0) for 20 min
followed by a peroxidase block with 0.03% hydrogen-per-
oxide methanol and an endogenous avidin-binding activ-
ity-block by incubation with avidin solution for 15 min
(one chicken egg white resuspended in 100 ml PBS) and
15 min in biotin solution (pasteurized cow milk), and di-
aminobenzidine development. Antibodies used included
biotinylated rabbit anti-mouse (DAKOCytomation, Glos-
trup, Denmark), goat anti-rabbit (DAKOCytomation),
biotinylated-peroxidase streptavidin complex (SABC;
DAKOCytomation), anti-HLA-A heavy chain mAb HCA2,
anti-HLA-B/C heavy chain mAb HC10 (supernatant
kindly provided by Dr. J. Neefjes, NKI, Amsterdam, The
Netherlands and Dr. H. L. Ploegh, MIT, MA, at 1:400 and
1:100 dilutions, respectively) [21,22], rabbit anti-β2-m
polyclonal Ab (A 072; DAKOCytomation; 167 μg/l), anti-
MLH1 (clone G168-728; BD Biosciences Pharmingen; 20
mg/l), and anti-PMS2 (clone A16-4; BD Biosciences
PharMingen, San Diego, CA, USA; 10 mg/l). Loss of
expression was defined as complete loss of staining in
both the membrane and cytoplasm (HCA2, HC10, and
anti-β2-m) or in the nucleus (anti-MLH1 and anti-PMS2)
with concurrent expression in normal epithelium, stroma,
or infiltrating leukocytes.
REV
MFI HLA MFI negative control
MFI vim HLA
= + − +
+ −
[ker ; ] [ker ; ]
[ ; ] MFI vim negative control[ ; ]+
Table 2: HLA genotype and phenotype of the 21 patients whose 
tumor tissue was used for flow cytometry.
case A.1 A.2 B.1 B.2
40 A2 A3 B15 B38
43 A2 A3 B18 B49
44 A2 A24 B7 B55
45 A1 A2 B8 B62
48 A3 A3 B7 B62
55 A1 A3 B8 B62
56 A1 A30 B8 B51
58 A2 A32 B44 B60
59 A1 A2 B7 B62
61* A2 Bw4 Bw6
63* A2 Bw4 Bw6
69 A2 A24 B7 B39
106* A3 Bw4 Bw6
108 A2 A68 B51 B53
109* A3 Bw4 Bw6
110 A1 A23 B8 B50
120 A2 A3 B7 B44
122 A1 A24 B44 B56
124* A2 Bw4
179 A3 A3 B7 B35
191 A2 A24 B15 B40
A.1, A.2, B.1 and B.2 indicate the different HLA A and B alleles. * HLA 
genotype was not known prior to tumor resection, phenotype based 
on flow cytometry of vim+ cells with mouse monoclonal antibodies 
(Table 1).Page 4 of 12
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Microsatellite instability (MSI) analysis was performed
and scored as described previously [23] using the markers
BAT25, BAT26, BAT40, D2S123, D5S346, D17S250,
MSH3 and MSH6. β2m frameshift analysis was performed
with primers (available upon request) build around cod-
ing repeats of the β2m gene; the (CT)4 repeat in exon 1
and two (A)5 repeats in exon 2[24]. Genomic DNA of
both normal and tumor tissue was isolated from 3 tissue
cores of 0.6 mm diameter of formalin-fixed, paraffin-
embedded material using the Chelex extraction method
[25].
Statistics
Values of significance were calculated using the software
package SPSS 10.0.7 (SPSS Inc., Chicago, IL, USA). We
performed Pearson Chi-square tests or, when expected
count was below 5, Fisher's exact 2-sided tests. The inde-
pendent sample t-test was performed to test equality of
means of the age at operation.
Results
Two patterns of alteration in HLA class I phenotype as 
observed by flow cytometry
Loss of expression of HLA class I alleles was observed in 8
of 21 (38%) colorectal cancer cases studied [see Addi-
tional file 1]. Two distinct patterns of HLA loss were iden-
tified; the loss of a single HLA-A or -B allele which was
observed in 4 of 8 cases (cases 61, 63, 109, and 191), and
the loss of both HLA-A and -B alleles which was observed
in the remaining 4 cases (cases 55, 56, 120, and 179).
Importantly, in the latter group, membranous expression
of β2-microglobulin (β2-M) and remaining HLA class I
antigens was retained in the 4 tumors, but was diminished
as determined with the mAbs BBM.1 and W6/32. In these
samples, the average Relative Expression Values (REV, see
Methods section) was 0.43 and 0.38, respectively, com-
pared to the average REVS of 2.9 and 2.2, respectively, in
the other 17 cases (Figure 1) [see also Additional file 1].
This would suggest the retention of at least one of the
other HLA class I alleles, i.e. HLA-C, -E, -F or -G.
Alterations of HLA phenotype are found in specific subsets 
of colorectal cancer
The 7 of 8 cases with HLA alterations were all right sided
(p = 0.024). Interestingly, all 5 MSI-H cases in the series
(5/21) demonstrated HLA alterations [see Additional file
1]. Four of the 5 cases demonstrated loss of HLA-A and -B
(p = 0.028); in 1 of the 5 cases, we observed the loss of a
single HLA allele (case 191). Loss of expression of the het-
erodimer of MLH1 and PMS2 was observed in the 4 MSI-
H cases through IHC, and was not observed in any other
cases [see Additional file 1]. These patients do not fulfill
any criteria indicative of HNPCC are thus most likely spo-
radic. Other clinicopathological features typical of spo-
radic MSI-H tumors [26] were also present; they occurred
in elderly patients (mean age 75 years, p = 0.043), 3 of 4
were located in the caecum (p = 0.019), and 3 of 4 were
peri-diploid (p = 0.053). The other MSI-H tumor (case
120) was located in the sigmoid, occurring in the setting
of the Hereditary Non-Polyposis Colorectal Cancer
(HNPCC) syndrome. A mutation in the Mut-S-Homologue
2 (MSH2) gene (G674R, exon 13 2020G>C) segregated in
this particular family, a variant that is probably patho-
genic. The abrogation of MSH2 expression in this tumor
was confirmed by IHC. Since all the 4 MSI-H tumors that
lost HLA A and B expression showed diminished mem-
branous expression of β2m we have screened the micros-
atellite sequences of the corresponding gene but failed to
find any frameshift mutation.
One case (case 55, MSI-H, multi-ploid) was particularly
intriguing. Ploidy studies indicated a peri-diploid tumor
cell population as well as an aneuploid population (Fig-
ure 2). Interestingly, while the aneuploid population
retained HLA expression for all HLA alleles examined, the
diploid population was characterized by two populations
of cells; one population that retained HLA expression, and
one population (the largest tumor cell population) that
demonstrated a loss of expression of both HLA-A and -B
alleles.
The 4 cases showing loss of both HLA-A and -B expression
have not presented with lymph node or distant metastases
to date, while 3 of the 4 cases with loss of a single allele
(including 1 MSI-H case) and 10 of the remaining 13
cases without alterations of the HLA phenotype, did
metastasize (p = 0.035) to either lymph nodes or to dis-
tant extranodal sites.
Comparison of FCM with conventional 
immunohistochemistry
Using FCM, we detected a significantly lower frequency of
HLA class I aberrations than previously reported [8-
10,27]. Consequently, we decided to compare our FCM
results with those obtained using conventional IHC. The
human anti-HLA mAbs used for flow cytometry could
clearly not be used for the IHC analyses due to high back-
ground staining caused by non-informative cross-reactiv-
ity of the secondary anti-human antibody. Consequently,
we chose to use a panel of mouse anti-HLA antibodies
(HCA2, HC10, anti-β2-m) for the IHC analyses, although
these are not alloantigen specific. Loss of expression of a
single HLA allele could not be detected using these anti-
bodies.
IHC of cases 55, 56, 120, and 179 (the 4 HLA-A and -B
negative cases) showed complete absence of HCA2 and
HC10 staining in tumor cells, and decreased anti-β2-m
staining which was primarily cytoplasmic (see Figure 3)Page 5 of 12
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Membranous HLA class I expression analysis by four-color multiparameter flow cytometry of colorectal tumor cell suspen-sionsFigure 1
Membranous HLA class I expression analysis by four-color multiparameter flow cytometry of colorectal tumor cell suspen-
sions. Fluorescence intensities of HLA class I with antibodies W6/32 (HC), BBM.1 (B2M), and alloantigen-specific antibodies 
against single A and B alleles (A.1 – B.2; see Table 2) are displayed in filled curves; corresponding negative controls are in non-
filled curves. A, keratin positive (ker+) epithelial cells are distinguished from vimentin positive (vim+) stroma cells and infiltrat-
ing leukocytes. DNA ploidy analysis of case 122 reveals an aneuploid ker+ tumor cell fraction (black) compared to the normal 
diploid vim+ cells (light gray). B, Expression of all HLA molecules tested in case 122 of both ker+, tumor (black), and vim+ 'nor-
mal' (gray) cells. C, loss of the single A.1 (HLA-A2) allele was observed for tumor cells in case 191. D, loss of expression of all 
4 HLA-A and -B alleles in tumor cells, but retention of HC and B2M, in case 179. The patient is homozygous for HLA-A3 (--
;see Table 2).
BMC Cancer 2006, 6:233 http://www.biomedcentral.com/1471-2407/6/233and, consequently, probably irrelevant since cytoplasmic
localization of HLA molecules is not functional. However,
membranous staining of HCA2, HC10, and anti-β2-m
was clearly observed in the adjacent stroma cells (positive
internal control). The FCM data would thus appear to cor-
roborate the IHC findings. Loss of staining was not
HLA phenotype alteration is associated with DNA ploidy of the cells within one tumorFigure 2
HLA phenotype alteration is associated with DNA ploidy of the cells within one tumor. Flow cytometry analysis of case 55 
reveals a synchronous divergence of tumor cell populations with DNA ploidy and HLA expression. Keratin positive (ker+, 
black) epithelial cells are distinguished from vimentin positive (vim+, light gray) stroma cells and infiltrating leukocytes (a). 
Compared to the diploid vim+ cells (b), peri-diploid and aneuploid cell populations of ker+ cells are revealed (c). By plotting 
HLA expression to DNA content, 3 ker+ cell populations can be discriminated, including a HLA negative DNA diploid tumor 
cell population and a HLA positive aneuploid population (d).Page 7 of 12
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Conventional HLA immunohistochemistry of formalin-fixed paraffin-embedded tissueFigure 3
Conventional HLA immunohistochemistry of formalin-fixed paraffin-embedded tissue. Using HCA2 (HLA-A heavy chain), 
HC10 (HLA-B/C heavy chain) and anti-B2M antibodies, loss of HLA A and B expression as detected by flow cytometry (see 
Figures 1 and 2) could be confirmed. In the top panel, membranous staining (arrows) of B2M, HCA2, and HC10 is observed in 
the moderately differentiated sigmoid adenocarcinoma of case 122. In the bottom panel, loss of HLA-A and -B is illustrated for 
the mucinous caecum adenocarcinoma of case 179. Tumor B2M staining was mainly restricted to the cytoplasm (arrow), but 
some membranous expression of B2M was observed by FCM (see Figure 1). The HCA2 and HC10 staining was completely lost 
in tumor epithelium (t). Typically, the retained HLA expression of stroma cells (s) resulted in an inverted staining pattern in 
comparison to case 122. HE, haematoxylin and eosin staining. Pictures were made at 400 × magnification, HEs at 100×.
BMC Cancer 2006, 6:233 http://www.biomedcentral.com/1471-2407/6/233observed in the remaining cases studied by IHC [see Addi-
tional file 1]. A heterogeneous staining pattern, i.e. both
positively and negatively staining tumor fields within the
same section, was frequently observed; such heterogeneity
in membranous expression was not observed as discrete
populations (peaks) in our FCM data.
Discussion
We used four-color multiparameter FCM to study com-
plete HLA-A and -B phenotypes in colorectal tumors using
a large panel of alloantigen-specific mAbs. FCM allows the
detection of variation in expression over a dynamic range
of 4 logarithmic decades and therefore FCM appears to be
very sensitive. Loss of membranous expression was
detected in 38% (8 of 21 cases) of tumors in our study.
Previous studies based on IHC demonstrated variable
alterations in up to 73% of cases [8-10,27]. This discrep-
ancy may be explained by the different technical
approaches used and/or by the different composition of
the groups under study (e.g. microsatellite stable/MSI-H
distribution, tumor staging).
Except for one case (case 55) our FCM data did not pro-
vide evidence for discrete intratumoral epithelial subpop-
ulations of differing HLA expression as was observed
using IHC, although the lognormal distribution of the
measured fluorescence may obscure these variations in
expression. Nevertheless, the heterogeneous IHC staining
patterns are difficult to interpret, and may be falsely
regarded as loss of expression.
Using FCM, we characterized two distinctive alterations in
colorectal tumors. We found 4 cases demonstrating loss of
a single HLA-A or B allele (alterations not identified
through immunohistochemistry), and 4 cases demon-
strating loss of expression of both the A and B alleles, but
not loss of all HLA class I molecules. The expression of
HLA I antigen complexes is a prerequisite for the optimal
targeting of tumor cells by CD8+ CTLs. However, NK cells
and CTLs also carry inhibitory receptors for specific HLA
class I alleles. Immunoselection thus relies on a delicate
balance between HLA allele loss and retention. Examples
of tumor immune escape due to such intricate alterations
of HLA phenotype have been described recently [16,28].
In tumors showing loss of a single allele in our study, this
loss was restricted to HLA-A2 in 3 of the 4 cases. HLA-A2
is not a ligand for inhibitory receptors. Those tumors may
have effectively shed (HLA-A2) restricted epitopes and
remained inhibitory to NK cell attack. Additionally, the 4
cases demonstrating loss of both HLA-A and -B alleles
(also applicable to the cases showing loss of a single
allele) retained expression of some total HLA class I mol-
ecules, which was detected through the W6/32 antibody
and might indicate retention of HLA-C or other non clas-
sical HLA molecules like HLA-G or -E.. Of these, HLA-E is
normally expressed in colon epithelial cells [29] and pre-
dominantly function as inhibitors of NK-cell function
[30]. These tumor cells may escape CTL attack and attack
by a subset of NK cells. HIV-1 infected cells, for example,
avoid both CTL and NK cell-mediated lysis through spe-
cific HLA-A and -B downregulation caused by the HIV-1
gene product nef [31]. These different phenotypic altera-
tions may reflect differences in local immune selective
forces between the tumor subsets. Such differences remain
to be identified.
All but one of the tumors with an altered HLA phenotype
were located on the right side of the colon. The exception
was a left sided tumor arising in the setting of HNPCC.
Furthermore, the loss of both HLA-A and -B alleles was
found exclusively in tumors with the MSI-H phenotype.
Mismatch repair deficiency has previously been associated
with frequent mutations in the β2-m gene (B2M)[24,32-
35]. This gene harbors multiple short tandem repeats that
are preferentially mutated, leading to total loss of mem-
branous HLA class I expression. However, we did not
observe frame shift mutations in these repeats in the MSI-
H tumors with HLA-A and -B loss, which is in line with the
retention of membranous staining (although diminished)
with the W6/32 and anti-β2-m mAbs. Yet, the common
loss of expression of HLA-A and -B in 3 of 4 sporadic MSI-
H tumors, which is not due to B2M frame shift mutations,
would suggest that another general mechanism may cause
this altered phenotype.
Sporadic MSI-H tumors are usually relatively large, but
rarely disseminate [3,36,37]. This favorable tumor behav-
ior has been associated with an increased intra-epithelial
CD8+ CTLs and CD57+ NK cells infiltrate when com-
pared with the microsatellite stable tumors. CD4+ cells
are not frequently found in the intraepithelial infiltrate of
MSI-H tumors. [24,38-42]. The MSI of numerous coding
microsatellites results in a large repertoire of immuno-
genic frame shift peptides which can give rise to specific
anti-tumor immune responses [4-6]. However, these infil-
trating lymphocytes may lead to the selection of HLA
alterations in tumor cells. High levels of infiltrate were
present in the HLA-A and -B negative cases in this study as
observed by microscopy. Alternatively, the observed T cell
infiltrate could represent an innocent bystander effect.
Previously, we identified loss of HLA-A and -B expression
in 6 of 88 cases of sporadic colorectal cancer using IHC
that, surprisingly, did not present with recurrences or
metastases during follow-up [27]. Although we could not
determine the exact HLA phenotypic alteration at that
time, the previous cases resemble the 3 sporadic MSI-H
cases found in this study that lacked HLA-A and -B expres-
sion and that have not presented with lymph node or dis-
tant metastases to date. The NK cells that reside in the
lymph and blood and that specifically kill metastasizingPage 9 of 12
(page number not for citation purposes)
BMC Cancer 2006, 6:233 http://www.biomedcentral.com/1471-2407/6/233tumor cells (that lack total HLA class I expression) may
explain the more favorable prognosis. However, the pos-
tulated expression of the remaining non HLA-A and -B
alleles by tumor cells may specifically inhibit these NK
cells.
Conclusion
FCM allows the discrimination of complex phenotypes
related to the expression of HLA class I. The different pat-
terns of HLA class I expression might underlie different
tumor behavior and influence the success rate of immu-
notherapy.
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